Discontinued — last reported Q1 '22
Products & Services · Upfront payment for collaboration agreement
BIIB115 — Upfront payment for collaboration agreement
Biogen BIIB115 — Upfront payment for collaboration agreement remained flat by 0.0% to $60.00M in Q1 2022 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ4 2021
Last reportedQ1 2022
How to read this metric
An increase in payments made signals aggressive investment in external innovation or pipeline expansion, while an increase in payments received signals successful monetization of internal R&D assets or intellectual property.
Detailed definition
This metric represents the initial, non-refundable cash consideration paid to a partner or received from a partner upon...
Peer comparison
Comparable to upfront licensing fees or milestone payments seen across the biopharmaceutical industry when companies enter into co-development or co-commercialization agreements.
Metric ID:
biib_segment_biib115_upfront_payment_for_collaboration_agreementHistorical Data
2 periods
| Q4 '21 | Q1 '22 | |
|---|---|---|
| Value | $60.00M | $60.00M |
| QoQ Change | — | +0.0% |
Range$60.00M – $60.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's biib115 — upfront payment for collaboration agreement?
- Biogen (BIIB) reported biib115 — upfront payment for collaboration agreement of $60.00M in Q1 2022.
- What does biib115 — upfront payment for collaboration agreement mean?
- The initial cash payment made or received at the start of a partnership or licensing deal for drug development or commercialization.